Pharmacokinetics and safety of evogliptin in hepatically impaired patients

Hong Taegon; Jin Byung Hak; Kim Choon Ok; Yoo Byung Won; Kim Dasohm; Lee Jung Il; Kim Beom Kyung; Ahn Sang Hoon; Kim Do Young; Park Jun Yong; Park Min Soo

首页> 外文期刊>British Journal of Clinical Pharmacology >Pharmacokinetics and safety of evogliptin in hepatically impaired patients

【24h】

Pharmacokinetics and safety of evogliptin in hepatically impaired patients

机译：Evogliptin在肝化患者中的药代动力学和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims Evogliptin is a potent and selective dipeptidyl peptidase-4 inhibitor for glycaemic control in patients with type 2 diabetes mellitus. Since evogliptin is mainly eliminated through hepatic metabolism, we investigated the pharmacokinetics (PKs) and safety characteristics of evogliptin in Korean patients with mild or moderate hepatic impairment.

机译：目的Evogliptin是一种有效且选择性的二肽基肽酶-4抑制剂，用于2型糖尿病患者的血糖控制。由于吴茱萸乙素主要通过肝脏代谢被清除，我们研究了吴茱萸乙素在韩国轻度或中度肝损伤患者中的药代动力学（PKs）和安全性特征。

著录项

来源
《British Journal of Clinical Pharmacology》 |2021年第7期|共10页
作者
Hong Taegon; Jin Byung Hak; Kim Choon Ok; Yoo Byung Won; Kim Dasohm; Lee Jung Il; Kim Beom Kyung; Ahn Sang Hoon; Kim Do Young; Park Jun Yong; Park Min Soo;
展开▼
作者单位

Yonsei Univ Severance Hosp Dept Clin Pharmacol Coll Med 50-1 Yonsei Ro Seoul 03722 South Korea;

Yonsei Univ Severance Hosp Dept Clin Pharmacol Coll Med 50-1 Yonsei Ro Seoul 03722 South Korea;

Yonsei Univ Severance Hosp Dept Clin Pharmacol Coll Med 50-1 Yonsei Ro Seoul 03722 South Korea;

Yonsei Univ Severance Hosp Dept Clin Pharmacol Coll Med 50-1 Yonsei Ro Seoul 03722 South Korea;

Yonsei Univ Severance Hosp Dept Clin Pharmacol Coll Med 50-1 Yonsei Ro Seoul 03722 South Korea;

Yonsei Univ Inst Gastroenterol Dept Internal Med Coll Med Seoul South Korea;

Yonsei Univ Inst Gastroenterol Dept Internal Med Coll Med Seoul South Korea;

Yonsei Univ Inst Gastroenterol Dept Internal Med Coll Med Seoul South Korea;

Yonsei Univ Inst Gastroenterol Dept Internal Med Coll Med Seoul South Korea;

Yonsei Univ Inst Gastroenterol Dept Internal Med Coll Med Seoul South Korea;

Yonsei Univ Severance Hosp Dept Clin Pharmacol Coll Med 50-1 Yonsei Ro Seoul 03722 South Korea;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
DPPamp; 8208; 4 inhibitor; evogliptin; hepatic impairment; pharmacokinetics; Type 2 diabetes mellitus;

机译：DPP＆amp;8208;4抑制剂;evogliptin;肝障碍;药代动力学;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling [J] . Guo-fu LI, Kun WANG, Rui CHEN, 中国药理学报：英文版 . 2012,第011期
2. Whole-body physiology-based pharmacokinetics of caspofungin for general patients,intensive care unit patients and hepatic insufficiency patients [J] . Qian-ting YANG, Ya-lin DONG, Ya-jing ZHAI, 中国药理学报：英文版 . 2018,第009期
3. Metabolism, pharmacokinetics, and hepatic disposition of xanthones and saponins on Zhimu treatments for exploratively interpreting the discrepancy between the herbal safety and timosaponin A3-induced hepatotoxicity [J] . Yang Xie, Xu Zhou, Hu Pei, 中国药理学报：英文版 . 2018,第012期
4. Phase 1 studies comparing safety,tolerability,pharmacokinetics and pharmacodynamics of HLX01(a rituximab biosimilar)to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma [J] . Yuankai Shi, Jifeng Feng, Xiaonan Hong, 中国癌症研究（英文版） . 2021,第003期
5. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer [J] . WU Jian-yu, WU Xiao-nan, DING Li, 中华医学杂志：英文版 . 2010,第007期
6. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial [J] . Calvo Emiliano, Azaro Analia, Rodon Jordi, Investigational new drugs. . 2018,第3期

机译：肝脏肝脏安全性分析：肝脏损伤患者患者肝癌患者药代动力学研究的结果及3期临床试验
7. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial [J] . Calvo Emiliano, Azaro Analia, Rodon Jordi, Investigational new drugs. . 2018,第3期

机译：肝脏肝脏安全性分析：肝脏损伤患者患者肝癌患者药代动力学研究的结果及3期临床试验
8. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment [J] . Grechko Nikolay, Skarbova Viera, Tomaszewska-Kiecana Monika, Cancer chemotherapy and pharmacology. . 2021,第2期

机译：高级实体肿瘤和肝损伤患者Rucaparib的药代动力学和安全性
9. MATURE MYSTERIES: "OLD AGE AIN'T NO PLACE FOR SISSIES" MANAGING OSTEOARTHRITIS IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT [C] . Gregory F. Grauer Annual Meeting of the American Animal Hospital Association . 2008

机译：成熟的谜团：“旧时代不是啜饮的地方”管理肾病或肝病患者骨关节炎
10. Design evaluation for pharmacokinetic studies in patients with renal impairment [D] . Liu, Jin 2007

机译：肾功能不全患者药代动力学研究的设计评估
11. Open‐label study to evaluate trifluridine/tipiracil safety tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment [O] . Muhammad Wasif Saif, Lee Rosen, Michelle A. Rudek, 2019

机译：开放性研究评估晚期实体瘤和肝功能不全患者中三氟吡啶/替普拉西酯的安全性耐受性和药代动力学
12. Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region [O] . Colby S. Shemesh, Phyllis Chan, Hui Shao, 2021

机译：atezolizumab和Bevacizumab在患有不可切除的肝细胞癌：基于肝损伤状态和地理区域的药代动力学和安全评估
13. Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function211 Study Design, Data Analysis, and Impact on Dosing and Labeling [R] . 1998

机译：工业指南。肾功能受损患者的药代动力学211研究设计，数据分析以及对剂量和标记的影响

Pharmacokinetics and safety of evogliptin in hepatically impaired patients

摘要

著录项

相似文献

相关主题

期刊订阅